SCHEMBL22800984

SCHEMBL22800984

Cc1ccc(C)c(CC(=O)N2CCN(c3nc4c(c(=O)[nH]c(=O)n4C)n3Cc3ccccc3F)CC2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GAA P10253 3/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.57
▸ HTT P42858 3/20 0.57
▸ MAPT P10636 2/20 0.57
▸ HSD17B10 Q99714 2/20 0.57
▸ LMNA P02545 1/20 0.57
▸ NPSR1 Q6W5P4 1/20 0.57
▸ PKM P14618 1/20 0.57
▸ ALDH1A1 P00352 7/20 0.54
▸ MEN1 O00255 3/20 0.53
▸ KMT2A Q03164 3/20 0.53
▸ TSHR P16473 5/20 0.53
▸ HPGD P15428 2/20 0.53
▸ USP2 O75604 2/20 0.51
▸ TP53 P04637 2/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ MAPK1 P28482 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22800926 0.88 GAA (0.58) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800996 0.88 HTT (0.67) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800985 0.86 HTT (0.63) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800950 0.86 HTT (0.71) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800911 0.83 PKM (0.57) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800923 0.82 PKM (0.66) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800900 0.79 DPP4 (0.74) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800904 0.78 PKM (0.66) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800922 0.78 PKM (0.68) GAAL3MBTL1HTTMAPTHSD17B10
SCHEMBL22800895 0.78 PKM (0.73) GAAL3MBTL1HTTMAPTHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578073-B2 Xanthine analogs as potent anti-West Nile viral agents SOUTHERN RESEARCH INSTITUTE (US) 2023-02-14 — — US disclosed
US-11578073-B2 Xanthine analogs as potent anti-West Nile viral agents SOUTHERN RESEARCH INSTITUTE (US) 2023-02-14 — — US disclosed
US-20200399271-A1 XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS OREGON HEALTH AND SCIENCE UNIVERSITY 2020-12-24 — — US disclosed
US-20200399271-A1 XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS OREGON HEALTH AND SCIENCE UNIVERSITY 2020-12-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399271-A1 XANTHINE ANALOGS AS POTENT ANTI-WEST NILE VIRAL AGENTS XDH, PNP, MAVS GAA 281/4885L3MBTL1 1137/4885HTT 2458/4885
US-11578073-B2 Xanthine analogs as potent anti-West Nile viral agents XDH, PNP, MAVS GAA 281/4885L3MBTL1 1137/4885HTT 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback